How Is Menopause Linked to an Increased Risk of Frozen Shoulder?

What Frozen Shoulder Actually Is

Frozen shoulder, formally called adhesive capsulitis, is a fibrotic contracture of the glenohumeral joint capsule that progressively restricts both active and passive range of motion. The condition moves through three overlapping phases: a painful "freezing" stage lasting 2 to 9 months, a "frozen" stage with profound stiffness lasting 4 to 12 months, and a gradual "thawing" stage that can take another 5 to 24 months [1]. Total duration from onset to resolution averages 30 months, though some patients never fully recover baseline motion.

The hallmark pathology is dense fibrosis of the rotundal interval and inferior capsule, with proliferation of fibroblasts and myofibroblasts, excessive type I and type III collagen deposition, and neovascularization [2]. Inflammatory cytokines (IL-1, IL-6, TNF-alpha) and growth factors (TGF-beta) are markedly elevated in capsular tissue biopsies from affected shoulders. This is not simple "wear and tear." It is an active fibroinflammatory process, and estrogen sits at the center of its regulation.

A 2022 systematic review in the Journal of Shoulder and Elbow Surgery reported that adhesive capsulitis affects 2% to 5.3% of the general population, with women representing a clear majority of cases [3]. The sex disparity becomes even more pronounced after age 45, exactly when ovarian estrogen production begins its steepest decline.

The Estrogen Connection

Estradiol is not just a reproductive hormone. It is a systemic anti-inflammatory and antifibrotic signaling molecule with receptors in virtually every musculoskeletal tissue, including the shoulder joint capsule. Both estrogen receptor alpha (ER-alpha) and estrogen receptor beta (ER-beta) have been identified in human glenohumeral capsular fibroblasts [4].

When circulating estradiol drops from premenopausal levels of 30 to 400 pg/mL down to postmenopausal levels consistently below 30 pg/mL, several downstream effects converge on the shoulder capsule. Estrogen normally suppresses nuclear factor kappa-B (NF-kB), a master regulator of inflammation. Without that suppression, NF-kB activity rises, increasing production of IL-6 and TNF-alpha within the capsule [5]. Estrogen also modulates TGF-beta signaling, the primary driver of fibroblast-to-myofibroblast transformation. Declining estrogen removes this brake, allowing TGF-beta to push capsular fibroblasts toward the collagen-overproducing myofibroblast phenotype that defines adhesive capsulitis [2].

A 2020 study published in Menopause (the journal of The North American Menopause Society) examined 5,103 postmenopausal women and found that those with the lowest serum estradiol quartile had a 2.07-fold increased odds of shoulder stiffness compared with the highest quartile (OR 2.07, 95% CI 1.23 to 3.49) [6]. That dose-response relationship is difficult to explain away as coincidence.

Dr. Vonda Wright, an orthopedic surgeon specializing in women's musculoskeletal health, has stated: "The shoulder is an estrogen-sensitive joint. When we see a 52-year-old woman with bilateral frozen shoulders and no trauma history, the hormonal transition is almost always a contributing factor" [7].

Why the Timing Lines Up So Precisely

The mean age of natural menopause in the United States is 51.4 years [8]. The mean age of frozen shoulder onset in women is 50 to 55 years [1]. This is not a coincidence of middle age. The temporal overlap reflects a direct biological relationship.

Perimenopause typically begins 4 to 8 years before the final menstrual period. During this window, estradiol levels fluctuate wildly before their terminal decline. These fluctuations may actually be more damaging to capsular tissue than a steady low level, because repeated cycles of inflammation activation and incomplete resolution promote cumulative fibrosis [9].

A large Taiwanese population-based cohort study (N = 9,135) published in 2021 found that women who underwent bilateral oophorectomy before age 45 (surgical menopause) had a 1.58-fold higher risk of developing adhesive capsulitis compared with age-matched women who retained their ovaries (HR 1.58, 95% CI 1.12 to 2.23) [10]. Surgical menopause produces an abrupt, complete estrogen withdrawal rather than the gradual decline of natural menopause, and the elevated frozen shoulder risk in this group further implicates estrogen deficiency as a causal mechanism.

The perimenopause also brings changes in progesterone, testosterone, and DHEA-S. Progesterone, which has its own anti-inflammatory properties, drops to near-zero after anovulatory cycles become the norm. DHEA-S, which serves as a precursor for local tissue estrogen synthesis, declines by roughly 2% per year from age 30 onward [11]. The shoulder capsule loses multiple layers of hormonal protection simultaneously.

Compounding Risk Factors in Menopausal Women

Estrogen decline rarely acts alone. Several conditions that cluster around menopause multiply frozen shoulder risk.

Type 2 diabetes. Insulin resistance increases during the menopausal transition due to loss of estrogen's insulin-sensitizing effects. A meta-analysis of 11 studies (combined N = 327,737) published in Diabetes Care found that diabetes increases frozen shoulder risk 2- to 4-fold, with diabetic adhesive capsulitis also being more resistant to treatment and more likely to recur [12]. The mechanism involves advanced glycation end-products (AGEs) cross-linking collagen fibers in the capsule, producing a stiffer, less compliant tissue.

Thyroid disease. Hypothyroidism and autoimmune thyroiditis are more common in postmenopausal women, and both independently raise adhesive capsulitis risk. A 2014 study in the Journal of Clinical Endocrinology & Metabolism reported that thyroid disease was present in 27.2% of frozen shoulder patients versus 10.3% of controls [13].

Cardiovascular risk factors. Dyslipidemia and elevated C-reactive protein, both of which increase after menopause, correlate with adhesive capsulitis. Systemic low-grade inflammation appears to lower the threshold for capsular fibrosis in a joint that is already losing its hormonal protection.

Sedentary behavior. Reduced physical activity during the menopausal transition decreases shoulder joint loading, which is necessary to maintain capsular flexibility. The American College of Sports Medicine recommends that postmenopausal women perform resistance training at least twice weekly, partly for musculoskeletal maintenance [14].

Does Hormone Replacement Therapy Protect the Shoulder?

This is one of the most clinically relevant questions at the intersection of menopause and musculoskeletal health. The evidence is observational but consistently directional.

A 2017 retrospective cohort analysis of 5,788 postmenopausal women in South Korea found that current users of menopausal hormone therapy (MHT) had a 35% lower odds of adhesive capsulitis compared with never-users (adjusted OR 0.65, 95% CI 0.48 to 0.88) [15]. The association persisted after adjusting for age, BMI, diabetes, and thyroid disease.

The 2022 North American Menopause Society position statement on hormone therapy notes that "estrogen therapy has well-documented anti-inflammatory effects on musculoskeletal tissues" and lists musculoskeletal symptom improvement as an observed benefit, though it is not currently listed as a primary indication for prescribing [16].

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the Women's Health Initiative hormone therapy trials, has observed: "Musculoskeletal pain is one of the most common symptoms of menopause, and the joint-protective effects of estrogen are biologically plausible and supported by observational data. We need randomized trials specifically designed to test this endpoint" [17].

No randomized controlled trial has yet tested HRT specifically for frozen shoulder prevention. The practical implication: HRT should not be prescribed solely to prevent adhesive capsulitis, but women already considering HRT for vasomotor symptoms, bone health, or other indications can be counseled that shoulder joint protection may be an additional benefit.

Diagnosis and When to Suspect a Hormonal Link

Frozen shoulder is a clinical diagnosis. The cardinal finding is a global restriction of both active and passive shoulder range of motion, especially external rotation and abduction, without a radiographic explanation. MRI can show capsular thickening and enhancement but is usually unnecessary for diagnosis [1].

Clinicians should suspect a hormonal contribution when the patient is a woman between 45 and 60, has no history of shoulder trauma or surgery, presents with insidious bilateral or sequential involvement, and has concurrent menopausal symptoms (hot flashes, sleep disruption, vaginal dryness). A hormonal panel showing estradiol below 30 pg/mL and elevated FSH above 30 mIU/mL supports the menopausal context.

Screening for diabetes (fasting glucose or HbA1c) and thyroid function (TSH) is appropriate in every frozen shoulder patient, because undiagnosed endocrine disease is common in this population and alters the treatment plan [13].

Treatment: Combining Musculoskeletal and Hormonal Approaches

Standard treatment for adhesive capsulitis follows a stepwise protocol.

Physical therapy is the foundation. A Cochrane review found that supervised physical therapy improves pain and function scores, though evidence quality was moderate [18]. The emphasis should be on gentle sustained stretching (pendulum exercises, cross-body stretches, wall walks) rather than aggressive manipulation, which can worsen capsular inflammation in the freezing stage.

Intra-articular corticosteroid injection. A single ultrasound-guided injection of 40 mg triamcinolone into the glenohumeral joint provides meaningful pain relief for 4 to 8 weeks and creates a window for more effective physical therapy. A randomized trial of 191 patients published in the BMJ found that corticosteroid injection combined with physical therapy was superior to either intervention alone at 12 weeks [19].

Hydrodilatation (distension arthrography) involves injecting saline and corticosteroid under pressure to mechanically stretch the contracted capsule. A 2020 meta-analysis in JBJS Reviews found that hydrodilatation produced greater short-term improvements in range of motion than corticosteroid injection alone [20].

Manipulation under anesthesia and arthroscopic capsular release are reserved for refractory cases that fail 6 to 12 months of conservative management. Outcomes are generally good, with 85% to 90% of patients achieving satisfactory motion, but surgical intervention carries risks of humeral fracture and nerve injury [1].

Addressing the hormonal context. For menopausal women with frozen shoulder, treatment should not be purely musculoskeletal. If HRT is appropriate for the patient's overall symptom profile and risk-benefit assessment, initiating systemic estrogen therapy (transdermal estradiol 0.05 mg/day with micronized progesterone for women with a uterus) may support capsular healing by restoring anti-inflammatory signaling [16]. The 2022 Endocrine Society clinical practice guideline for menopausal hormone therapy supports its use in symptomatic women within 10 years of menopause onset or under age 60 [21].

Blood glucose optimization is equally important. In diabetic patients with frozen shoulder, bringing HbA1c below 7.0% correlates with better treatment response and lower recurrence rates [12].

Prevention Strategies for Women in the Menopausal Transition

Prevention is under-discussed in clinical practice. Several evidence-informed strategies can reduce frozen shoulder risk during the hormonal transition.

Maintain shoulder mobility. Daily overhead reaching, wall slides, and doorway stretches maintain capsular flexibility. Even 5 minutes per day matters.

Resistance training. Loading the rotator cuff and deltoid with band exercises or light dumbbells 2 to 3 times per week improves local blood flow and collagen turnover [14].

Metabolic health. Tight glucose control, maintaining a healthy BMI, and treating dyslipidemia reduce the systemic inflammatory burden that primes the capsule for fibrosis.

Prompt evaluation. Any new shoulder stiffness in a perimenopausal or postmenopausal woman deserves evaluation within 2 to 4 weeks of onset. Early intervention during the freezing stage (corticosteroid injection plus physical therapy) can shorten the disease course by months.

Discuss HRT timing. The window for starting systemic estrogen therapy is widest within 10 years of menopause or before age 60, when cardiovascular risk is lowest and musculoskeletal benefit is greatest [21]. Women experiencing early shoulder stiffness alongside vasomotor symptoms should discuss hormone therapy with their clinician as part of a comprehensive menopausal care plan.

Women who have undergone surgical menopause (bilateral oophorectomy) before age 45 should be counseled specifically about frozen shoulder risk and strongly considered for estrogen therapy unless contraindicated, given their abrupt and complete hormone loss [10].